Top of this page
Skip navigation, go straight to the content
Scroll down to discover UCB
Seletalisib (UCB5857)
| Disease area studied |
Abbreviated title | Phase | Study ID | Registry database | Study results | Plain language summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| APDS |
An Open-Label, Exploratory, Multicenter, Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics and Efficacy of UCB5857 in Subjects with Activated Phosphoinositide 3 Kinase (PI3K) Delta Syndrome (APDS) |
APD003 Terminated |
2015-005541-30 |
LINK |
|||
| Sjogren´s Syndrome | A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjorgen's Syndrome |
SS0004 Terminated |
NCT02610543 2014-004523-51 |
|
Juarez M., Diaz N., Johnston G.I., Nayar S., Payne A. et al. heumatology (Oxford) 2020 [ePub] |